Sarepta Therapeutics
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage clinical trial. The biopharmaceutical company revealed that its Phase 3 ESSENCE study, evaluating the efficacy of its Duchenne muscular dystrophy (DMD) therapies Amondys
